Vanda Pharmaceuticals Inc. (VNDA) — SEC Filings
Vanda Pharmaceuticals Inc. (VNDA) — 50 SEC filings. Latest: 10-Q (May 7, 2026). Includes 31 8-K, 7 10-Q, 3 DEFA14A.
View Vanda Pharmaceuticals Inc. on SEC EDGAR
Overview
Vanda Pharmaceuticals Inc. (VNDA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: Vanda Pharmaceuticals Inc. filed an 8-K on December 30, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, with a business phone number of (202) 734-3400. The co
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Vanda Pharmaceuticals Inc. is neutral.
Filing Type Overview
Vanda Pharmaceuticals Inc. (VNDA) has filed 7 10-Q, 1 EFFECT, 31 8-K, 3 DEFA14A, 2 DEF 14A, 2 10-K, 1 8-K/A, 3 SC 13G/A with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of VNDA's 41 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 27 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $158.889M |
| Net Income | $-79.287M |
| EPS | N/A |
| Debt-to-Equity | 0.29 |
| Cash Position | $70.022M |
| Operating Margin | N/A |
| Total Assets | $601.140M |
| Total Debt | $135.141M |
Key Executives
- Mihael H. Polymeropoulos, M.D.
- Phaedra S. Chrousos
Industry Context
The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often rely on a few key products for revenue, making pipeline development and market exclusivity crucial. The competitive landscape includes both large, established pharmaceutical giants and smaller biotechnology firms, all vying for market share and innovation.
Top Tags
sec-filing (9) · pharmaceuticals (6) · 8-K (5) · 8-k (5) · 10-Q (5) · disclosure (5) · corporate-governance (4) · proxy-statement (4) · financials (4) · financial-reporting (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Fiscal Year End | 1231 | Indicates the end of the company's financial reporting year. |
| Net Product Sales (Q3 2025) | $56.258M | Increased 18.06% from $47.651M in Q3 2024 |
| Net Loss (Q3 2025) | $22.586M | Increased 324.22% from $5.324M in Q3 2024 |
| Selling, General and Administrative Expenses (Q3 2025) | $60.273M | Increased 60.4% from $37.573M in Q3 2024 |
| Research and Development Expenses (Q3 2025) | $22.563M | Increased 34.5% from $16.776M in Q3 2024 |
| Net Loss (YTD Sep 2025) | $79.287M | Widened from $13.988M in YTD Sep 2024 |
| Net Cash Used in Operating Activities (YTD Sep 2025) | $80.025M | Increased from $13.940M in YTD Sep 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $70.022M | Decreased from $102.316M at Dec 31, 2024 |
| Total Revenues (YTD Sep 2025) | $158.889M | Increased from $145.587M in YTD Sep 2024 |
| Q2 2025 Net Loss | $10.5M | Increased from $5.2M in Q2 2024, indicating worsening profitability. |
| Q2 2025 Revenue | $55.3M | Decreased from $60.1M in Q2 2024, primarily due to lower Fanapt sales. |
| YTD 2025 Net Loss | $18.7M | Wider than $9.8M YTD 2024 net loss, showing sustained unprofitability. |
| YTD 2025 Total Revenues | $110.5M | Down from $118.9M YTD 2024, reflecting overall sales decline. |
| Q2 2025 R&D Expenses | $18.2M | Increased from $16.5M in Q2 2024, indicating continued investment in pipeline. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
Frequently Asked Questions
What are the latest SEC filings for Vanda Pharmaceuticals Inc. (VNDA)?
Vanda Pharmaceuticals Inc. has 50 recent SEC filings from Feb 2024 to May 2026, including 31 8-K, 7 10-Q, 3 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VNDA filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 46 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Vanda Pharmaceuticals Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vanda Pharmaceuticals Inc. (VNDA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vanda Pharmaceuticals Inc.?
Key financial highlights from Vanda Pharmaceuticals Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VNDA?
The investment thesis for VNDA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vanda Pharmaceuticals Inc.?
Key executives identified across Vanda Pharmaceuticals Inc.'s filings include Mihael H. Polymeropoulos, M.D., Phaedra S. Chrousos.
What are the main risk factors for Vanda Pharmaceuticals Inc. stock?
Of VNDA's 41 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 27 low-risk.
What are recent predictions and forward guidance from Vanda Pharmaceuticals Inc.?
Forward guidance and predictions for Vanda Pharmaceuticals Inc. are extracted from SEC filings as they are enriched.